ClinicalTrials.gg
Not yet recruitingNCT07382375Updated Feb 2, 2026

AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection

An interventional study of Ulinastatin and Thymalfasin and Ulinastatin in Aortic Aneurysm and Dissection, sponsored by Nanjing Medical University. Not yet recruiting at 8 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Nanjing Medical University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a "subtyping-target-treatment" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies (treatment of physician's choice). It observes 7-day postoperative SOFA score, SIRS and other prognostic indicators to provide evidence-based support for precision treatment.

02

Conditions studied

  • Aortic Aneurysm and Dissection

Keywords

  • inflammation
  • immune
03

In context

Aortic Dissection

205 studies on the registry are indexed under Aortic Dissection; 73 are open to participants now.

This study's planned enrollment of 300 is above the median of 114 across 86 interventional studies indexed under Aortic Dissection.

Browse Aortic Dissection studies →

Lead sponsor

Nanjing Medical University is the lead sponsor of 171 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of acute aortic dissection by contrast-enhanced Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA);
  2. Planned emergency surgical treatment (including open surgery and endovascular repair);
  3. Aged 18-80 years old, regardless of gender;
  4. Time from onset to hospital admission ≤ 72 hours;
  5. Signed form by the patient or their authorized agent, with willingness to cooperate with the follow-up of the study.

Exclusion criteria

Exclusion Criteria:

  1. Complicated with underlying diseases that affect immunoinflammatory status, such as severe infections (e.g., sepsis, infective endocarditis), diseases, malignant tumors, chronic liver diseases, and chronic kidney diseases (uremic stage);
  2. Long-term use of or before surgery (continuous use for ≥ 2 weeks);
  3. Pregnant or lactating women;
  4. Patients with mental disorders or cognitive dysfunction who cannot cooperate with the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Subtyping-based precision therapy

    * Balanced type (HIS1): No anti-inflammatory intervention required; * Inflammation-excessive type (HIS2): Anti-inflammatory intervention with ulinastatin; ③ Immunosuppressive type (HIS3): Immunomodulation with thymalfasin; ④ Mixed reaction type (HIS4): Combined treatment with ulinastatin and thymalfasin.

    Drug: Ulinastatin and Thymalfasin

  • Active comparator
    Conventional Empirical Strategy

    treatment of physician's choice alone

    Drug: Ulinastatin

Interventions

  • DrugUlinastatin and Thymalfasin

    Drug pages: Urinastatin · Thymalfasin

    AI-assisted Immunoinflammatory Subtyping-guided Target-matching Individualized Anti-inflammatory Strategy

  • Conventional empirical regimens will be formulated based on patients' clinical symptoms and routine inflammatory indicators (white blood cell count, C-reactive protein, procalcitonin) without uniform target-matching standards, with reference to clinical diagnosis and treatment guidelines: if obvious inflammatory responses are present (e.g., fever, significant elevation of C-reactive protein), non-steroidal anti-inflammatory drugs or low-dose glucocorticoids will be administered; if complicated with infection, combined antibiotic therapy will be given; for patients with normal or slightly elevated inflammatory indicators, anti-inflammatory drugs may be temporarily withheld, and close monitoring will be performed instead. The regimen will be adjusted according to changes in routine inflammatory indicators after surgery until the patient is discharged.

06

What researchers measure

Primary outcomes

  1. Sequential Organ Failure Assessment (SOFA) score. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure.

    The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure.

    Time frame: 7 days after surgery

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07382375
Collaborators
The First Affiliated Hospital with Nanjing Medical University, The Third Affiliated Hospital of Soochow University, West China Hospital, Fujian Medical University Union Hospital, Shanghai East Hospital, Beijing Anzhen Hospital, Second Affiliated Hospital of Nanchang University
Responsible party
Hong Liu (Principal Investigator of Department of Cardiovascular Surgery, Nanjing Medical University) — Principal investigator
First posted
Feb 2, 2026
Start date
Dec 31, 2027 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

Sheng Zhao
Contact
zhaosheng0824@njmu.edu.cn
18801281613
Guo-laing Fan, MD
Contact
smartmanliang@sina.com
Yong-feng Shao
study director · The First Affiliated Hospital with Nanjing Medical University
Hong Liu
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Urinastatin · Thymalfasin

Start the discussion